Astellas India Gets Nod for PADCEV Combo in Urothelial Cancer
Astellas Pharma India announced CDSCO approval of PADCEV (enfortumab vedotin) plus pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer, showing superior survival vs chemotherapy.


